Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1236 in Moderate to Severe COPD
NCT00758706Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD1236 with Placebo (2 arms). Primary endpoints: Ratio of TNF Alpha at Week 6 to Baseline, Ratio of Sputum Total Cells at Week 6 to Baseline and 1 more. Started Sep 2008; status: completed.
02
Drugs
AZD1236
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00758706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758706.